That is very encouraging news, shows they have the money to increase clinical sites and pursue trial for K-OC. 10 patients undergoing 6 weeks of follow up. Hopefully, trial can be completed by end of 2017. Additionally, toxicology and PK/PD data for oral conversion and oral formulation development should allow for quicker and cheaper oral phase 2 study in 2018. This development may very likely attract some BP partnership.
3 different drugs for multiple indications/platforms. Risk/Reward is extremely favorable, especially at current prices. I added recently to an already large holding. I remain long and strong.
News 
Market Data 
Discover 
AI
